[go: up one dir, main page]

ATE526994T1 - Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten - Google Patents

Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten

Info

Publication number
ATE526994T1
ATE526994T1 AT09170183T AT09170183T ATE526994T1 AT E526994 T1 ATE526994 T1 AT E526994T1 AT 09170183 T AT09170183 T AT 09170183T AT 09170183 T AT09170183 T AT 09170183T AT E526994 T1 ATE526994 T1 AT E526994T1
Authority
AT
Austria
Prior art keywords
antigen
fusion proteins
contain
protease activity
mtb32a
Prior art date
Application number
AT09170183T
Other languages
English (en)
Inventor
Yasir Skeiky
Steven Reed
Mark Alderson
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/597,796 external-priority patent/US7186412B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE526994T1 publication Critical patent/ATE526994T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT09170183T 2000-06-20 2001-06-20 Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten ATE526994T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/597,796 US7186412B1 (en) 1998-04-07 2000-06-20 Fusion proteins of Mycobacterium tuberculosis
US26573701P 2001-02-01 2001-02-01

Publications (1)

Publication Number Publication Date
ATE526994T1 true ATE526994T1 (de) 2011-10-15

Family

ID=40253655

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09170183T ATE526994T1 (de) 2000-06-20 2001-06-20 Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
AT01946661T ATE442866T1 (de) 2000-06-20 2001-06-20 Fusionsproteine aus mycobakterium tuberculosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01946661T ATE442866T1 (de) 2000-06-20 2001-06-20 Fusionsproteine aus mycobakterium tuberculosis

Country Status (14)

Country Link
US (7) US7083796B2 (de)
EP (2) EP1542732B1 (de)
JP (2) JP5139618B2 (de)
AT (2) ATE526994T1 (de)
AU (2) AU6867801A (de)
CA (1) CA2413959C (de)
CY (2) CY1109531T1 (de)
DE (1) DE60139963D1 (de)
DK (2) DK1542732T3 (de)
ES (2) ES2333579T3 (de)
HK (1) HK1080506A1 (de)
PT (2) PT1542732E (de)
SI (1) SI1542732T1 (de)
WO (1) WO2001098460A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
DK1517913T3 (da) * 1999-10-07 2007-06-18 Corixa Corp En Mycobacterium tuberculosis-kodende sekvens til ekspression af heterologe proteiner
CA2386841A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EP1542732B1 (de) 2000-06-20 2009-09-16 Corixa Corporation Fusionsproteine aus mycobakterium tuberculosis
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EA012037B1 (ru) 2004-11-16 2009-06-30 Круселл Холланд Б.В. Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
WO2006117538A2 (en) * 2005-04-29 2006-11-09 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
US8470338B2 (en) * 2005-04-29 2013-06-25 Glaxosmithkline Biologicals, S.A. Method for preventing or treating M tuberculosis infection
AU2011224145B2 (en) * 2005-04-29 2013-05-16 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating M tuberculosis infection
UA107788C2 (en) * 2005-04-29 2015-02-25 Glaxosmithkline Biolog Sa A fusion protein of m. tuberculosis
WO2007041539A1 (en) * 2005-09-30 2007-04-12 Transcutaneous Technologies, Inc. Iontophoresis apparatus and method for the diagnosis of tuberculosis
WO2008124647A2 (en) 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
WO2009049097A1 (en) * 2007-10-13 2009-04-16 Cornell University Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis
KR101378240B1 (ko) * 2008-02-22 2014-03-28 포항공과대학교 산학협력단 결핵 예방용 조성물
EA201100070A1 (ru) 2008-07-25 2011-10-31 Глаксо Груп Лимитед Туберкулезный белок rv2386c, композиции и их применения
CN102164952B (zh) 2008-07-25 2016-05-25 葛兰素史密丝克莱恩生物有限公司 新型组合物和方法
EA022203B1 (ru) 2008-07-25 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Способы и композиции для лечения или предупреждения туберкулёза
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген
MX344280B (es) 2010-12-14 2016-12-09 Glaxosmithkline Biologicals Sa Composicion antigenica de micobacteria.
EP2771469A4 (de) * 2011-10-24 2015-04-08 Univ Central Florida Res Found An choleratoxin-b-untereinheit kondeniserte plastid-exprimierte mycobacterium-tuberkuloseimpfstoffantigene esat-6 und mtb72f
EP2812704A4 (de) * 2012-02-07 2016-03-23 Intuitive Biosciences Inc Mycobakteriumstuberkulose-spezifische peptide zur erkennung einer infektion oder immunisierung nichtmenschlicher primaten
MX347154B (es) 2012-02-24 2017-02-21 Centro De Investigación Científica Y De Educación Superior De Ensenada Baja California (Cicese) Prueba de diagnóstico para enfermedades infecciosas en ganado bovino.
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5856073A (en) 1973-06-28 1975-01-30 Toru Tsumits Tuberculin active proteins and peptides
FR2244539A1 (en) 1973-07-13 1975-04-18 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
FR2265402A1 (en) 1974-03-29 1975-10-24 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4876089A (en) 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4689397A (en) 1985-08-12 1987-08-25 Scripps Clinic And Research Foundation Synthetic polypeptides for detecting mycobacterial infections
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4976958A (en) 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
WO1989006280A1 (en) 1988-01-04 1989-07-13 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5108745B1 (en) 1988-08-16 1998-06-30 Univ California Tuberculosis and legionellosis vaccines and methods for their production
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP1645635A3 (de) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replikationdefiziente Rekombinante Retroviren, die eine palliative Wirkung exprimieren
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
EP0419355B1 (de) 1989-09-19 2000-02-09 N.V. Innogenetics S.A. Rekombinante Polypeptide und Peptide, dafür kodierende Nukleinsäuren und ihre Verwendung in der Tuberkulose-Diagnose
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP0553288B1 (de) 1990-10-18 1997-06-18 Cellpro Incorporated Vorrichtung und verfahren zur trennung von partikeln mittels eines biegsamen gefässes
ES2104731T3 (es) 1990-11-08 1997-10-16 Univ London Micobacterium utilizado como adyuvante para antigenos.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
RU2024021C1 (ru) 1991-05-05 1994-11-30 Научно-исследовательский институт хирургии Восточно-Сибирского филиала СО РАМН Способ диагностики туберкулеза
DE4116249A1 (de) 1991-05-17 1992-11-19 Biotechnolog Forschung Gmbh Hybrid-plasmid fuer m.-tuberculosis-antigen, e. coli als wirt und antigen
WO1993004175A1 (en) 1991-08-15 1993-03-04 Smithkline Beecham Biologicals (S.A.) Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DK0641192T3 (da) 1992-05-18 1998-03-02 Minnesota Mining & Mfg Anordning til transmucosal lægemiddelafgivelse
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DK0761231T3 (da) 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5330754A (en) 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
NL9202197A (nl) 1992-12-17 1994-07-18 Kreatech Biotech Bv Werkwijze en inrichting voor het identificeren van een voor een mycobacteriële infectie verantwoordelijk mycobacterium species.
CA2153391C (en) 1993-01-11 2000-08-15 Kenneth Rock Inducing cytotoxic t lymphocyte responses
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5616500A (en) 1993-04-30 1997-04-01 The United States Of America As Represented By The Department Of Health & Human Services Trichohyalin and transglutaminase-3 and methods of using same
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6008201A (en) 1993-09-02 1999-12-28 Cornell Research Foundation, Inc. DNA molecule encoding for cellular uptake of mycobacterium tuberculosis and uses thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5783386A (en) 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5551622A (en) 1994-07-13 1996-09-03 Yoon; Inbae Surgical stapler
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
DE4446509A1 (de) 1994-12-24 1996-06-27 Sel Alcatel Ag Verfahren zur Herstellung von Leiterbahnen auf einem Vertiefungen aufweisenden Substrat
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5714593A (en) 1995-02-01 1998-02-03 Institut Pasteur DNA from mycobacterium tuberculosis which codes for a 45/47 kilodalton protein
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
AU706367B2 (en) 1995-03-13 1999-06-17 Astra Aktiebolag New DNA molecules
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (de) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. VERBESSERTER VERFAHREN ZUR HERSTELLUNG VON cDNA-SEQUENZEN MIT VOLLER LÄNGER
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
DK2154248T3 (da) 1995-09-01 2012-01-30 Corixa Corp Forbindelser og fremgangsmåder til diagnose af tuberkulose
NZ319377A (en) 1995-09-01 2000-01-28 Corixa Corp polypeptides comprising a portion of a soluble M tuberculosis antigen
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US20020068285A1 (en) 1996-01-11 2002-06-06 Frudakis Tony N. Compositions and methods for the therapy and diagnosis of breast cancer
CA2249742A1 (en) 1996-03-15 1997-09-18 Steven G. Reed Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
TR199901569T2 (xx) 1996-10-11 2000-12-21 Corixa Corporation T�berk�lozun te�hisi i�in bile�ikler ve y�ntemler.
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DK1584685T3 (da) 1998-02-05 2011-07-11 Glaxosmithkline Biolog Sa Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
HU228354B1 (en) 1998-04-07 2013-03-28 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and their uses
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
CA2340174C (en) 1998-08-10 2011-01-04 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US8143386B2 (en) 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
AU6158700A (en) * 1999-07-13 2001-01-30 Corixa Corporation Vaccine
DK1517913T3 (da) * 1999-10-07 2007-06-18 Corixa Corp En Mycobacterium tuberculosis-kodende sekvens til ekspression af heterologe proteiner
CA2386841A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2001034802A2 (en) 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP2003528591A (ja) 2000-01-14 2003-09-30 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
CA2403909A1 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1542732B1 (de) 2000-06-20 2009-09-16 Corixa Corporation Fusionsproteine aus mycobakterium tuberculosis
DE60328083D1 (de) 2002-02-14 2009-08-06 Mitsui Chemicals Inc Polyesterharz und katalysator für die polyesterherstellung, verfahren zur herstellung von polyesterharz mit dem katalysator.
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7301098B2 (en) 2005-01-19 2007-11-27 Panduit Corp. Communication channels with suppression cores
EP1734111B1 (de) * 2005-06-13 2020-06-24 Tosoh Corporation Zellfusionsvorrichtung und Verfahren zur Zellfusion unter Verwendung derselben
US7296798B2 (en) 2006-01-31 2007-11-20 Matt Overfield Gameboard, games played on board and methods of play requiring strategy and luck
DE102007005223A1 (de) * 2006-02-10 2007-09-13 Continental Teves Ag & Co. Ohg Motor-Pumpenaggregat
JP4630844B2 (ja) * 2006-05-29 2011-02-09 パナソニック株式会社 光ピックアップ装置
CN102549336B (zh) 2009-07-21 2014-11-26 库柏技术公司 将发光二极管(led)模块连接于散热器组件、反光件以及电路
US9119754B2 (en) 2011-10-08 2015-09-01 Michael Dennis Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en) 2013-10-28 2015-06-09 Ford Global Technologies, Llc Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9810514B2 (en) 2015-09-08 2017-11-07 Deufol Sunman Inc. Ammunition carrier consumer package

Also Published As

Publication number Publication date
US7083796B2 (en) 2006-08-01
AU2001268678B2 (en) 2006-11-16
US20090004226A1 (en) 2009-01-01
AU6867801A (en) 2002-01-02
EP2133100A1 (de) 2009-12-16
US20060193876A1 (en) 2006-08-31
DE60139963D1 (de) 2009-10-29
CY1112171T1 (el) 2015-12-09
CA2413959A1 (en) 2001-12-27
US20080317716A1 (en) 2008-12-25
ES2374620T3 (es) 2012-02-20
JP2012034695A (ja) 2012-02-23
JP5139618B2 (ja) 2013-02-06
EP1542732B1 (de) 2009-09-16
PT2133100E (pt) 2012-01-11
US20100015096A1 (en) 2010-01-21
US8071747B2 (en) 2011-12-06
US20080161263A1 (en) 2008-07-03
US20040086523A1 (en) 2004-05-06
US7976844B2 (en) 2011-07-12
ATE442866T1 (de) 2009-10-15
WO2001098460A3 (en) 2004-10-28
EP2133100B1 (de) 2011-10-05
EP1542732A2 (de) 2005-06-22
SI1542732T1 (sl) 2010-01-29
JP2004526405A (ja) 2004-09-02
CA2413959C (en) 2015-07-07
ES2333579T3 (es) 2010-02-24
DK2133100T3 (da) 2012-01-23
DK1542732T3 (da) 2009-12-14
US20090018095A1 (en) 2009-01-15
HK1080506A1 (en) 2006-04-28
US7973153B2 (en) 2011-07-05
WO2001098460A2 (en) 2001-12-27
CY1109531T1 (el) 2014-08-13
PT1542732E (pt) 2009-11-06
EP1542732A4 (de) 2005-11-02

Similar Documents

Publication Publication Date Title
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
Rajapakse et al. Immunization with the RgpA-Kgp proteinase-adhesin complexes of Porphyromonas gingivalis protects against periodontal bone loss in the rat periodontitis model
Austrian Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines
HUP0101521A2 (hu) A Mycobacterium tuberculosis antigének fúziós fehérjéi és felhasználásuk
ATE443768T1 (de) Impfstoff gegen staphylokokken-vergiftung
ATE229978T1 (de) Helicobacter proteine und impstoffe
DE69636487D1 (de) Zusammensetzungen zur Immuntherapie und Diagnose von Tuberculosis
DE3886506D1 (de) Avirulente mikroben und deren verwendungen.
HUP0104774A2 (hu) Sztreptokokkusz antigének
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
BR9711457A (pt) Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
ITFI920052A1 (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
DK524289D0 (da) Fremgangsmaade til diagnosticering for og vaccine mod mycobakterier
Schoel et al. Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to Mycobacterium tuberculosis antigens separated by high-resolution techniques
ATE520713T1 (de) Identifizierung und veränderung von immundominanten polypeptidepitopen
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
DE69515340D1 (de) Impfstoff gegen mycobakterielle infektionen
FR2677365B1 (fr) Proteines de mycobacterium et applications.
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
AR019785A1 (es) Pestivirus no diseminantes
WO1999039693A3 (en) Methods and compositions for detection and diagnosis of infectious diseases
DK1077999T3 (da) Moraxella catarrhalis-proteiner
Khoo et al. Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts.
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2133100

Country of ref document: EP